CCThe Chemours Company
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.
Priced for ~2% a year FCF growth. Little growth is priced in even as revenue fell 3% a year over three years, potential value, or a value trap.
Expensive vs its own history: P/E 218.9 vs a 9.0 median over 26 quarters (+2338% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CC's price assumes
Today's price asks for 1.6% free cash flow growth a year; over the last three years The Chemours Company delivered 23%, less than the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 6.8%
Free cash flow yield · Specialty Chemicals median 4.7%
- Growth the price implies
- +1.6%
Growth the price implies · The price pays for +1.6% free cash flow growth a year for a decade; the business has delivered +23% a year over the last three.
- EV / sales
- 1.11
EV / sales
Details›
- EV / EBIToperating margin −1.9%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 1.11
- Free cash flow, trailing twelve months
- $218M
- Market capitalisation
- $3.21B
- 3-year revenue growth
- −2.9%
- 3-year free cash flow growth
- +23%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Specialty Chemicals
Ranks #24 of 33 by RyuScore